低剂量地西他滨治疗骨髓增生异常综合征的疗效观察
|
摘要
目的:探讨低剂量地西他滨(DAC)治疗骨髓增生异常综合征(MDS)的疗效与安全性。方法:将60例MDS患者随机分为观察组和对照组各30例,观察组给予低剂量DAC治疗,对照组给予预激方案治疗。治疗2个疗程后评价两组的疗效及不良反应。结果:观察组缓解率显著高于对照组(P<0.05);观察组NEUT<0.5×109平均时间、PLT<0.5×109平均时间及达到缓解平均时间均显著短于对照组(P<0.01);两组患者不良反应比较,差异无统计学意义(P>0.05)。结论:低剂量DAC治疗MDS的近期疗效显著,且不良反应耐受,是MDS安全有效的疗法。
Objective: To investigate clinical efficacy and safety of low-dose Decitabine( DAC) in treatment of myelodysplastic syndromes( MDS). Methods: 60 MDS patients were randomly divided into observation group and control group,30 cases in each group. The observation group was given low dose DAC treatment,while the control group was given priming regimen treatment. After 2 courses of the treatment,the curative effects and adverse reactions of the two groups were evaluated. Results: The remission rate of the observation group was significantly higher than that of the control group( P<0.05). The NEUT < 0.5× 109 mean time,PLT< 0.5× 109 median time,and median time to remission of the observation group were significantly shorter than those of the control group( P <0.05). There was no significant difference in the adverse reactions between the two groups( P>0.05). Conclusions: Low dose DAC is effective in the treatment of MDS with tolerated adverse reactions. Therefore,it is a safe and effective treatment for MDS.
Objective: To investigate clinical efficacy and safety of low-dose Decitabine( DAC) in treatment of myelodysplastic syndromes( MDS). Methods: 60 MDS patients were randomly divided into observation group and control group,30 cases in each group. The observation group was given low dose DAC treatment,while the control group was given priming regimen treatment. After 2 courses of the treatment,the curative effects and adverse reactions of the two groups were evaluated. Results: The remission rate of the observation group was significantly higher than that of the control group( P<0.05). The NEUT < 0.5× 109 mean time,PLT< 0.5× 109 median time,and median time to remission of the observation group were significantly shorter than those of the control group( P <0.05). There was no significant difference in the adverse reactions between the two groups( P>0.05). Conclusions: Low dose DAC is effective in the treatment of MDS with tolerated adverse reactions. Therefore,it is a safe and effective treatment for MDS.
引文
[1]Greenberg PL,Garcia-Manero G,Moore M,et al.A randomized controlled trial of romiplostim in patients with low-or intermediate-risk myelodysplastic syndrome receiving decitabine[J].Leukemia&lymphoma,2013,54(2):321-328.
[2]谭振清,罗自勉,周新伏.低剂量地西他滨治疗骨髓增生异常综合征的疗效分析[J].现代肿瘤医学,2012,20(8):1682-1685.
[3]张之南,沈悌.血液病诊断及疗效标准[M].北京:科学出版社,2007:168-169.
[4]Pusic I,Choi J,Bernabe N,et al.Maintenance Therapy With Decitabine After Allogeneic Hematopoietic Stem Cell Transplantation For Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome[J].Blood,2013,122(21):4638-4638.
[5]肖蓉.小剂量地西他滨治疗老年低增生性高危骨髓增生异常综合征1例[J].中国肿瘤临床,2010,37(21):1231.
[6]方宝枝,刘真真,何广胜,等.减低剂量地西他滨对输血依赖性低危骨髓增生异常综合征的临床疗效[J].中华医学杂志,2013,93(40):3189-3192.
[7]高雅,平宝红,周淑芸.地西他滨治疗老年骨髓增生异常综合征1例并文献复习[J].南方医科大学学报,2012,32(2):280-282.
[8]谢伟成,程淑琴,林翠芳,等.地西他滨治疗骨髓增生异常综合征的临床疗效研究[J].临床和实验医学杂志,2014(11):877-880.
[9]徐瑜,沙颖豪,谢彦晖.地西他滨联合小剂量化疗治疗老年中高危骨髓增生异常综合征及急性髓系白血病的临床观察[J].老年医学与保健,2013,19(1):31-33.
[10]Radivoyevitch T,Saunthararajah Y.Sex difference in myelodysplastic syndrome survival and balance in randomized clinical trials[J].J Clin Oncol,2014,32(1):60-61.
[2]谭振清,罗自勉,周新伏.低剂量地西他滨治疗骨髓增生异常综合征的疗效分析[J].现代肿瘤医学,2012,20(8):1682-1685.
[3]张之南,沈悌.血液病诊断及疗效标准[M].北京:科学出版社,2007:168-169.
[4]Pusic I,Choi J,Bernabe N,et al.Maintenance Therapy With Decitabine After Allogeneic Hematopoietic Stem Cell Transplantation For Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome[J].Blood,2013,122(21):4638-4638.
[5]肖蓉.小剂量地西他滨治疗老年低增生性高危骨髓增生异常综合征1例[J].中国肿瘤临床,2010,37(21):1231.
[6]方宝枝,刘真真,何广胜,等.减低剂量地西他滨对输血依赖性低危骨髓增生异常综合征的临床疗效[J].中华医学杂志,2013,93(40):3189-3192.
[7]高雅,平宝红,周淑芸.地西他滨治疗老年骨髓增生异常综合征1例并文献复习[J].南方医科大学学报,2012,32(2):280-282.
[8]谢伟成,程淑琴,林翠芳,等.地西他滨治疗骨髓增生异常综合征的临床疗效研究[J].临床和实验医学杂志,2014(11):877-880.
[9]徐瑜,沙颖豪,谢彦晖.地西他滨联合小剂量化疗治疗老年中高危骨髓增生异常综合征及急性髓系白血病的临床观察[J].老年医学与保健,2013,19(1):31-33.
[10]Radivoyevitch T,Saunthararajah Y.Sex difference in myelodysplastic syndrome survival and balance in randomized clinical trials[J].J Clin Oncol,2014,32(1):60-61.